X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs WOCKHARDT LTD. - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA WOCKHARDT LTD. AUROBINDO PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 18.2 -20.9 - View Chart
P/BV x 4.6 2.1 215.8% View Chart
Dividend Yield % 0.3 0.0 18,747.4%  

Financials

 AUROBINDO PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
WOCKHARDT LTD.
Mar-18
AUROBINDO PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs8951,012 88.4%   
Low Rs622532 117.0%   
Sales per share (Unadj.) Rs254.6355.9 71.5%  
Earnings per share (Unadj.) Rs39.3-60.3 -65.2%  
Cash flow per share (Unadj.) Rs46.6-46.8 -99.6%  
Dividends per share (Unadj.) Rs2.500.01 25,000.0%  
Dividend yield (eoy) %0.30 25,436.7%  
Book value per share (Unadj.) Rs160.0257.8 62.0%  
Shares outstanding (eoy) m585.88110.63 529.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.02.2 137.4%   
Avg P/E ratio x19.3-12.8 -150.8%  
P/CF ratio (eoy) x16.3-16.5 -98.7%  
Price / Book Value ratio x4.73.0 158.4%  
Dividend payout %6.40 -38,366.4%   
Avg Mkt Cap Rs m444,39085,379 520.5%   
No. of employees `00014.06.3 223.6%   
Total wages/salary Rs m17,6789,371 188.6%   
Avg. sales/employee Rs Th10,667.86,295.0 169.5%   
Avg. wages/employee Rs Th1,264.31,498.3 84.4%   
Avg. net profit/employee Rs Th1,645.8-1,066.3 -154.4%   
INCOME DATA
Net Sales Rs m149,15739,369 378.9%  
Other income Rs m1,1591,202 96.4%   
Total revenues Rs m150,31640,571 370.5%   
Gross profit Rs m34,34318 187,665.6%  
Depreciation Rs m4,2761,495 286.0%   
Interest Rs m6672,555 26.1%   
Profit before tax Rs m30,558-2,830 -1,079.9%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m7,597257 2,955.8%   
Profit after tax Rs m23,012-6,669 -345.1%  
Gross profit margin %23.00 49,533.1%  
Effective tax rate %24.9-9.1 -273.7%   
Net profit margin %15.4-16.9 -91.1%  
BALANCE SHEET DATA
Current assets Rs m92,06233,796 272.4%   
Current liabilities Rs m66,22326,917 246.0%   
Net working cap to sales %17.317.5 99.1%  
Current ratio x1.41.3 110.7%  
Inventory Days Days10679 133.6%  
Debtors Days Days6889 75.8%  
Net fixed assets Rs m62,91939,664 158.6%   
Share capital Rs m586553 105.9%   
"Free" reserves Rs m93,13327,968 333.0%   
Net worth Rs m93,71928,522 328.6%   
Long term debt Rs m1,81421,731 8.3%   
Total assets Rs m162,49481,620 199.1%  
Interest coverage x46.8-0.1 -43,527.9%   
Debt to equity ratio x00.8 2.5%  
Sales to assets ratio x0.90.5 190.3%   
Return on assets %14.6-5.0 -289.1%  
Return on equity %24.6-23.4 -105.0%  
Return on capital %32.7-7.7 -426.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,8389,807 773.3%   
Fx outflow Rs m30,2241,789 1,689.8%   
Net fx Rs m45,6138,019 568.9%   
CASH FLOW
From Operations Rs m32,786684 4,790.4%  
From Investments Rs m-17,8706,302 -283.5%  
From Financial Activity Rs m-19,153-7,695 248.9%  
Net Cashflow Rs m-4,239-664 638.4%  

Share Holding

Indian Promoters % 54.1 74.5 72.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.3 345.7%  
FIIs % 27.7 7.7 359.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.2 15.4 66.2%  
Shareholders   69,601 67,757 102.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  AJANTA PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red, Oil on the Boil, and Top Stocks in Action(Pre-Open)

The BSE Sensex closed lower by 53 points to end the day at 36,305. While the broader NSE Nifty ended the day down by 136 points to end at 10,975.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 25, 2018 09:13 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - BIOCON LTD COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS